VE-4840, an oral plasma kallikrein inhibitor, decreases human plasma kallikrein and VEGF-induced retinal thickening and vascular permeability

被引：0

作者：

Calton, Melissa A. ^{[1
]}

Ma, Jeffrey A. ^{[1
]}

Igoudin, Lev ^{[1
]}

Sizikov, Sivan ^{[1
]}

Chang, Eric ^{[1
]}

Rienzo, Matthew ^{[1
]}

Chang, Stephanie ^{[1
]}

To, Elaine E. ^{[1
]}

Zalicki, Piotr J. ^{[1
]}

Keutzer, Samuel ^{[1
]}

Estiarte, M. Angels ^{[1
]}

Shiau, Timothy P. ^{[1
]}

Sivaraja, Mohan ^{[1
]}

Datta, Anirban ^{[1
]}

Kita, David B. ^{[1
]}

机构：

[1] Verseon Co, Fremont, CA USA

来源：

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2019年 / 60卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

2725

引用

页数：4

共 14 条

[1] An orally dosed plasma kallikrein inhibitor decreases retinal vascular permeability in a rat model of diabetic retinopathy
Calton, Melissa A.
Ma, Jeffrey A.
Chang, Eric
Litt, Jeffrey
Chang, Stephanie S.
Estiarte, M. Angels
Shiau, Timothy P.
Datta, Anirban
Kita, David B.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
[2] Novel oral plasma kallikrein (PKa) inhibitors KV998052 and KV998054 ameliorate VEGF-induced retinal thickening in a murine model of retinal edema
Murugesan, Nivetha
Clermont, Allen C.
Pethen, Stephen J.
Li, Lily
Duckworth, Edward J.
Hampton, Sally L.
Feener, Edward
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
[3] Plasma Kallikrein Mediates Retinal Vascular Dysfunction and Induces Retinal Thickening in Diabetic Rats
Clermont, Allen
Chilcote, Tamie J.
Kita, Takeshi
Liu, Jia
Riva, Priscilla
Sinha, Sukanto
Feener, Edward P.
DIABETES, 2011, 60 (05) : 1590 - 1598
[4] Plasma Kallikrein Mediates Vascular Endothelial Growth Factor-Induced Retinal Dysfunction and Thickening
Clermont, Allen
Murugesan, Nivetha
Zhou, Qunfang
Kita, Takeshi
Robson, Peter A.
Rushbrooke, Louise J.
Evans, D. Michael
Aiello, Lloyd Paul
Feener, Edward P.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (06) : 2390 - 2399
[5] A novel oral plasma kallikrein (PKal) inhibitor KV123833 blocks VEGF-mediated retinal vascular hyperpermeability in a murine model of retinal edema
Murugesan, Nivetha
Clermont, Allen C.
Rushbrooke, Louise J.
Robson, Peter A.
Thoonen, Robrecht
Pethen, Stephen J.
Hampton, Sally L.
Feener, Edward P.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
[6] Plasma Kallikrein Deficiency is protective against diabetes induced retinal vascular dysfunction
Clermont, Allen
Zhou, Qunfang
Kita, Takeshi
Liu, Jia
Aiello, Lloyd
Feener, Edward
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
[7] Novel oral plasma kallikrein inhibitor KV998076 is protective against intravitreal VEGF and TNFα induced retinal edema and neuroretinal dysfunction
Murugesan, Nivetha
Clermont, Allen C.
Pethen, Stephen
Li, Lily
Duckworth, Edward
Hampton, Sally L.
Feener, Edward
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
[8] Plasma Kallikrein Mediates Angiotensin II Type 1 Receptor-Stimulated Retinal Vascular Permeability
Phipps, Joanna A.
Clermont, Allen C.
Sinha, Sukanto
Chilcote, Tamie J.
Bursell, Sven-Erik
Feener, Edward P.
HYPERTENSION, 2009, 53 (02) : 175 - U127
[9] The Novel, Specific Small-Molecule Plasma Kallikrein Inhibitor ASP-440 Normalizes Retinal Vascular Permeability in Streptozotocin-Induced Diabetes
Chilcote, Tamie J.
Clermont, Allen C.
Feener, Edward P.
Sinha, Sukanto
DIABETES, 2010, 59 : A166 - A166
[10] A Regulatory Role for -Secretase in VEGF-Induced Retinal Vascular Permeability via Phosphorylation of the VE-Cadherin Complex
Wu, L.
Cai, J.
Grant, M. B.
Boulton, M. E.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)

← 1 2 →